Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

61509 1497862462HCLSReviewTaiwanJune2017.pdf
Energy Boardroom

ATS 2014: InterMune, Boehringer face off in IPF

19.05.2014 / Scripintelligence

InterMune's idiopathic pulmonary fibrosis (IPF) drug pirfenidone may have a survival benefit over Boehringer Ingelheim's IPF treatment nintedanib, but Phase III results presented at the American Thoracic Society (ATS) 2014 Conference in San Diego make it…

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: